Leipziger Straße 44
39120 Magdeburg, de
+49 (391) 6117-352
IMTM Strengthens Patent Position for PETIR(TM) Drugs in Europe and USAMagdeburg, )
The US patents protect the company rights of PETIR(TM) based therapy for the treatment of autoimmune diseases and transplant rejection as well as for the modulation of regulatory T cells. The European patent captures new small molecular chemical entities as prodrugs of dual enzyme inhibitors currently under preclinical and clinical development. The company presently holds an aggregate of 11 patent families around the PETIR(TM) core technology.
IMTM has developed PETIR(TM) (peptidase targeted immune regulation), a novel and unique therapeutic platform to treat chronic inflammation, allergies and autoimmune diseases. PETIR(TM) drugs comprise the capacity to inhibit different cellular target enzymes within one single small molecular chemical compound. PETIR(TM) therapy leads to a decreased activity of inflammatory cells and, in parallel, an activation of natural anti-inflammatory immune cells, the regulatory T cells. This synergistic response induces an outstandingly efficient inhibition of inflammation.
Prof. Dr. Siegfried Ansorge and Dr. Michael Täger, General Managers of the company commented: "We are extremely delighted about this significant strengthening of our patent portfolio. In parallel to ongoing clinical trials of our first-in-class topical compound in psoriasis and acne and to the preparations for a first in men study of the first oral PETIR(TM) drug in inflammatory bowel diseases, we now have achieved a very strong IP position especially for our most advanced development compounds from the group of dual PETIR(TM) prodrugs."
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.